Galectin Therapeutics (GALT) Current Assets (2010 - 2026)
Galectin Therapeutics' quarterly Current Assets came in at $15.7 million in Q1 2026, up 68.99% year-on-year from $9.3 million in Q1 2025, and down 19.27% quarter-over-quarter from $19.4 million in Q4 2025.
Galectin Therapeutics has reported Current Assets for 17 years, with the latest figure at $15.7 million in Q1 2026.
- For the quarter ending Q1 2026, Current Assets rose 68.99% year-over-year to $15.7 million; the trailing twelve-month figure through Mar 2026 stood at $15.7 million (up 68.99% YoY), and the FY2025 full-year result was $19.4 million, up 12.66% from the prior year.
- Current Assets for Q1 2026 stood at $15.7 million, down from $19.4 million in the prior quarter.
- The five-year high for Current Assets was $33.5 million in Q1 2022, with the low at $9.3 million in Q1 2025.
- Average Current Assets over 5 years is $21.0 million, with a median of $19.6 million recorded in 2023.
- Year-over-year, Current Assets slumped 63.53% in 2025 and jumped 68.99% in 2026.
- Tracing GALT's Current Assets over 5 years: stood at $20.6 million in 2022, then jumped by 34.83% to $27.7 million in 2023, then sank by 37.74% to $17.3 million in 2024, then gained by 12.66% to $19.4 million in 2025, then retreated by 19.27% to $15.7 million in 2026.
- The last three Current Assets figures came in at $15.7 million (Q1 2026), $19.4 million (Q4 2025), and $12.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 10.37 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 37.31 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 1.25 Bn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 73.04 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 3.59 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 11.73 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 18.21 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 4.22 Bn |
| 10 | Galectin Therapeutics | 165.77 Mn | 151.67 Mn | - | 15.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.69 Mn |
| Dec 31, 2025 | 19.44 Mn |
| Sep 30, 2025 | 12.73 Mn |
| Jun 30, 2025 | 15.43 Mn |
| Mar 31, 2025 | 9.29 Mn |
| Dec 31, 2024 | 17.25 Mn |
| Sep 30, 2024 | 28.67 Mn |
| Jun 30, 2024 | 27.29 Mn |
| Mar 31, 2024 | 25.46 Mn |
| Dec 31, 2023 | 27.71 Mn |
| Sep 30, 2023 | 21.61 Mn |
| Jun 30, 2023 | 19.47 Mn |
| Mar 31, 2023 | 19.55 Mn |
| Dec 31, 2022 | 20.55 Mn |
| Sep 30, 2022 | 17.12 Mn |
| Jun 30, 2022 | 25.79 Mn |
| Mar 31, 2022 | 33.51 Mn |
| Dec 31, 2021 | 41.82 Mn |
| Sep 30, 2021 | 38.00 Mn |
| Jun 30, 2021 | 33.33 Mn |
| Mar 31, 2021 | 22.79 Mn |
| Dec 31, 2020 | 29.47 Mn |
| Sep 30, 2020 | 33.88 Mn |
| Jun 30, 2020 | 41.12 Mn |
| Mar 31, 2020 | 43.88 Mn |
| Dec 31, 2019 | 48.21 Mn |
| Sep 30, 2019 | 50.47 Mn |
| Jun 30, 2019 | 52.70 Mn |
| Mar 31, 2019 | 7.48 Mn |
| Dec 31, 2018 | 8.83 Mn |
| Sep 30, 2018 | 10.53 Mn |
| Jun 30, 2018 | 11.04 Mn |
| Mar 31, 2018 | 4.67 Mn |
| Dec 31, 2017 | 3.82 Mn |
| Sep 30, 2017 | 7.01 Mn |
| Jun 30, 2017 | 9.33 Mn |
| Mar 31, 2017 | 14.00 Mn |
| Dec 31, 2016 | 15.79 Mn |
| Sep 30, 2016 | 16.11 Mn |
| Jun 30, 2016 | 18.24 Mn |
| Mar 31, 2016 | 22.78 Mn |
| Dec 31, 2015 | 26.40 Mn |
| Sep 30, 2015 | 21.50 Mn |
| Jun 30, 2015 | 26.67 Mn |
| Mar 31, 2015 | 29.96 Mn |
| Dec 31, 2014 | 29.66 Mn |
| Sep 30, 2014 | 31.29 Mn |
| Jun 30, 2014 | 34.51 Mn |
| Mar 31, 2014 | 36.75 Mn |
| Dec 31, 2013 | 10.69 Mn |
| Sep 30, 2013 | 9.74 Mn |
| Jun 30, 2013 | 5.19 Mn |
| Mar 31, 2013 | 7.16 Mn |
| Dec 31, 2012 | 9.52 Mn |
| Sep 30, 2012 | 11.15 Mn |
| Jun 30, 2012 | 13.22 Mn |
| Mar 31, 2012 | 15.43 Mn |
| Dec 31, 2011 | 6.50 Mn |
| Sep 30, 2011 | 8.00 Mn |
| Jun 30, 2011 | 8.06 Mn |
| Dec 31, 2010 | 6.20 Mn |